DCA Uncovers Unlicensed Manufacturing Unit for Glycoril Cough Syrup

Thursday, 12 September 2024, 19:10

DCA has uncovered an unlicensed unit producing Glycoril cough syrup. This shocking discovery highlights critical regulatory failures concerning cough syrup production. DCA's actions aim to enhance public safety and ensure compliance in the pharmaceutical industry.
LivaRava_Trends_Default.png
DCA Uncovers Unlicensed Manufacturing Unit for Glycoril Cough Syrup

Shocking Discovery by DCA

The recent operation conducted by DCA led to the bust of an unlicensed manufacturing unit in Kukatpally, responsible for producing Glycoril cough syrup, a product that has raised concerns due to its unauthorized status.

Details of the Operation

  • Location: Prashanth Nagar, Kukatpally
  • Product: Glycoril cough syrup
  • Authority: DCA
  • Concerns: Public health and safety implications due to unregulated production

This incident not only poses risks to consumers but also underscores the importance of strict regulations in the pharmaceutical industry. DCA's vigilance serves as a reminder of the need for compliance with health standards.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest insights and trends from around the world. Stay informed and elevate your global perspective effortlessly.

Subscribe